Follow us :

Customize Membrane Protein Production for Research Prospects

time2014/03/20

The concept that “Same size fits all” is fading away in all industries, especially for the biology industry in terms of increasingly advanced and personalized requirements on researches and applications.

Customization or personalization is also moving with the time. Creative Biomart has profound expertise and experience to customize Membrane Protein Production for their prospects and customers.

Customization involves using technology to accommodate the differences between customers’ unique purposes and requirements. Using FoldEZTM technology, issues associated with the discovery of therapeutics for low abundance membrane proteins, and primarily GPCRs and ion channels can be accomplished.

Creative Biomart's proprietary FoldEZTM technology utilizes an E. coli expression system designed to enhance expression and to direct the recombinant protein to cytosolic aggregates known as "inclusion bodies”. This enables a yield of up to 10,000 fold higher than seen with conventional recombinant membrane protein expression technologies. Yields using this method are typically between 5-50 mg per liter of cell culture medium. The aggregated recombinant protein is then taken through a series of proprietary purification and refolding steps to generate functional, native protein.

With FoldEZTM , multiple targets or multiple variants of a given membrane protein target can be produced quickly and in a parallel format. To date, more than 200 different GPCRs and ion channels have been cloned and expressed using FoldEZTM. The current rate of success in expression and refolding is more than 75% for any given new protein and has been steadily increasing in the past.

Obviously if you are looking to have customized membrane protein service, FoldEZTM will be the popular choice with Creative Biomart enterprise.

FoldEZTM is the basis of drug discovery technologies such as protein structure analysis and the generation of therapeutic antibodies directed against GPCRs.